AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9607529
Drug: Intravenous cephazolin
RxNorm normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cephazolin 1 g every 6 h and gentamicin 80 mg every 8 h for 7 days
Trial: 9607529
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics until the appearance of infective complications
Trial: 7530585
Drug: Nevirapine 200
RxNorm normalized name: nevirapine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nevirapine 200 mg/day in combination with zidovudine 200 mg q8h
Trial: 7530585
Drug: Nevirapine at
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine at doses of 12.5, 50, and 200 mg/day
Trial: 7530585
Drug: Nevirapine alone
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nevirapine alone or in combination with zidovudine
Trial: 2223677
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral salbutamol (74 women)
Trial: 23829508
Drug: HM30181 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM30181 at doses ≥10 mg
Trial: 23829508
Drug: HM30181 (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM30181 (1, 5, 10, 15 mg)
Trial: 15655271
Drug: Continuous simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous simvastatin 10 mg/day for four months
Trial: 15655271
Drug: Intermittent simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent simvastatin 20 mg three times a week for four months
Trial: 10754624
Drug: Fentanyl concentration
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl concentration of 0.72 +/- 0.07 ng/ml
Trial: 10754624
Drug: Fentanyl concentration
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl concentration of 0.94 +/- 0.06 ng/ml
Trial: 1845927
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy for primary sclerosing cholangitis
Trial: 30022574
Drug: Drug Monograph
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Monograph
Trial: 28475268
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (standard treatment)
Trial: 27281811
Drug: PRO+EX (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO+EX (40 g protein with evening physical activity)
Trial: 27281811
Drug: PRO (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO (40 g protein without evening physical activity)
Trial: 31996267
Drug: Ojeok-san plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ojeok-san plus Saengmaek-san (5.76 g, three times per day for 6 weeks)
Trial: 28105731
Drug: liraglutide (1.8 mg/d)
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liraglutide (1.8 mg/d)
Trial: 25770176
Drug: Oral ergocalciferol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ergocalciferol, 50,000 IU weekly (n=36)
Trial: 25770176
Drug: Oral ergocalciferol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ergocalciferol, 50,000 IU monthly (n=33)
Trial: 25770176
Drug: Oral ergocalciferol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ergocalciferol, 50,000 IU weekly
Trial: 25770176
Drug: Oral ergocalciferol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ergocalciferol, 50,000 IU monthly
Trial: 15955039
Drug: Epidural blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blood patch (EBP) performed on day 2
Trial: 15955039
Drug: Epidural blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blood patch (EBP) performed on day 3
Trial: 15955039
Drug: Epidural blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blood patch (EBP) performed on day 4
Trial: 12601664
Drug: Routine therapy-motor
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy-motor training for upper-limb use and upper-limb stretches (5 days a week).
Trial: 9447855
Drug: Aprotinin (1.106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (1.106 KIU bolus followed by 5 x 10(5) KIU/h infusion)
Trial: 31957965
Drug: Extended dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended dual antiplatelet therapy (DAPT) beyond 12 months
Trial: 26492058
Drug: Intraoperative Steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative Steroid Administration
Trial: 22665903
Drug: Vandetanib 300
RxNorm normalized name: vandetanib 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vandetanib 300 mg/d orally
Trial: 19650804
Drug: Ropivacaine 13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 13 mg
Trial: 19650804
Drug: Ropivacaine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 10 mg plus sufentanil 5 microg
Trial: 19095139
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (target LDL-C <= 100 mg/dl)
Trial: 12032392
Drug: loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: loading dose clopidogrel (450 mg)
Trial: 12032392
Drug: aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin + ticlopidine post-stenting
Trial: 12032392
Drug: aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin + abciximab + ticlopidine post-stenting
Trial: 10073848
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (no revascularization)
Trial: 7888514
Drug: Thiopentone (4-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4-6 mg.kg‐1)
Trial: 7888514
Drug: Propofol (2-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2-2.5 mg.kg‐1)
Trial: 96062
Drug: Neutron-telecobalt therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron-telecobalt therapy
Trial: 96062
Drug: Telecobalt therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telecobalt therapy
Trial: 19496838
Drug: Topical gluco-oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gluco-oligosaccharide and collagen tripeptide F
Trial: 14505916
Drug: Botulinum F
RxNorm normalized name: botulinum neurotoxin F immune FAB2
DrugBank: Equine Botulinum Neurotoxin F Immune FAB2 (DB13901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum F toxoid vaccine (Bot F) administered 1-3 times
Trial: 14505916
Drug: Botulinum F
RxNorm normalized name: botulinum neurotoxin F immune FAB2
DrugBank: Equine Botulinum Neurotoxin F Immune FAB2 (DB13901)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum F toxoid vaccine (Bot F) administered 3 times over 28-42 days
Trial: 14505916
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of Botulinum F toxoid vaccine (Bot F) administered at 1 year
Trial: 14505916
Drug: Licensed, alum-adsorbed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licensed, alum-adsorbed hepatitis B vaccine (Engerix-B)
Trial: 8632929
Drug: Nebulized budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nebulized budesonide (4 mL, 2 mg)
Trial: 8632929
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 mL of 0.9% saline solution)
Trial: 1483494
Drug: +/- Nicardipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: +/- Nicardipine 50 mg b.d.
Trial: 1483494
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release nifedipine 20 mg b.d.
Trial: 31508899
Drug: Imipenem/relebactam 500/250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/relebactam 500/250 mg administered as a 30-minute intravenous infusion four times daily.
Trial: 29215518
Drug: Low-Molecular-Weight Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Molecular-Weight Heparin + Aspirin
Trial: 24657003
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus trastuzumab
Trial: 24657003
Drug: Pathological complete
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pathological complete response with chemotherapy alone
Trial: 20814327
Drug: Persistent medication
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Persistent medication refusal (114 patients, 18.8%)
Trial: 16087788
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg per day administered on awakening
Trial: 16087788
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg per day administered at bedtime
Trial: 16087788
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg per day administered at bedtime in non-dipper patients
Trial: 16087788
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg per day administered at bedtime in dipper patients
Trial: 10383561
Drug: Microencapsulated aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Microencapsulated aspirin 162.5 mg
Trial: 10383561
Drug: Aspirin EC
RxNorm normalized name: Aspirin EC
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin EC 150 mg
Trial: 10383561
Drug: Aspirin EC
RxNorm normalized name: Aspirin EC
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin EC 75 mg
Trial: 18958842
Drug: rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosiglitazone (8 mg daily)
Trial: 10860192
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (nisoldipine or enalapril)
Trial: 10860192
Drug: Moderate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate therapy (nisoldipine or enalapril)
Trial: 9217378
Drug: Methylprednisolone 500
RxNorm normalized name: methylprednisolone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 500 mg administered 2 hours before operation (group S)
Trial: 9217378
Drug: No pre-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre-treatment (group C)
Trial: 3403101
Drug: L-carnitine (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (1-g doses twice daily for 45 days)
Trial: 29402258
Drug: Home-based play-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based play-assisted stimulation for 1 hour during weekly home visits over 6 months
Trial: 27305924
Drug: 240 J
RxNorm normalized name: Vitamin J
DrugBank: Choline (DB00122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 240 J dose of near-infrared (NIR) light therapy
Trial: 31551349
Drug: Sham dose
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham dose
Trial: 23837606
Drug: Goal-directed hemodynamic
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed hemodynamic treatment (GDHT)
Trial: 23837606
Drug: Routine fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine fluid treatment
Trial: 20946674
Drug: Tutoring by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tutoring by a combination of content experts for 11 sessions and process experts for 10 sessions (n = 3)
Trial: 18257904
Drug: Non-ribavirin treatment
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non-ribavirin treatment (Control B)
Trial: 16414295
Drug: Alfentanil (25ng/ml
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (25ng/ml and 75ng/ml)
Trial: 16414295
Drug: Morphine (0.14mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.14mg/kg and 0.28mg/kg)
Trial: 9300118
Drug: Topical budesonide
RxNorm normalized name: budesonide Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical budesonide during active treatment periods in children with asthma (aged 12-16 years)
Trial: 8337162
Drug: Intravenous lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lorazepam (Ativan)
Trial: 8337162
Drug: Intravenous prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prochlorperazine (Compazine)
Trial: 3095557
Drug: Enteral feeding
RxNorm normalized name: enteral feeding dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral feeding via needle catheter jejunostomy (N.C.J.) with an elemental diet (Vivonex HN) starting at 18 hours and advanced to 3,000 ml/day (3,000 kcal, 20 gm N2) within 72 hours.
Trial: 30232858
Drug: Moxibustion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxibustion treatment (30 min, once daily, 6 times a week for 30 days)
Trial: 30232858
Drug: Donepezil hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil hydrochloride (5 mg/night for 30 days)
Trial: 27532525
Drug: Fluconazole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (two doses of 300mg given 1 week apart)
Trial: 27532525
Drug: Fluconazole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (two doses of 300mg given 1 week apart) + Ketoconazole shampoo (one application)
Trial: 24418570
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation (NMES) applied bilaterally to the quadriceps muscles, n = 11, 8 weeks, 5 days/week, twice/day, 45 min/session
Trial: 18397984
Drug: Berberine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine (1.0 g daily)
Trial: 12005274
Drug: Frovatriptan (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan (0.5, 1, 2.5, or 5 mg)
Trial: 12005274
Drug: Frovatriptan (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan (all doses)
Trial: 9347681
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1800 mg of eicosapentanoic acid [EPA] + 1200 mg of docosahexanoic acid) with garlic powder (1200 mg) capsules daily for 1 month
Trial: 8516490
Drug: Nitrendipine (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (calcium antagonist)
Trial: 29064409
Drug: Eicosapentaenoic acid/Docosahexaenoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) diet (10:1 plus supplement)
Trial: 29064409
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet (2:1 + S)
Trial: 26216528
Drug: Endogenous molecules
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endogenous molecules (metabolites such as tryptophan, alanine, arachidonic acid, 2-hydroxybutyric acid, cholesterol, and isoleucine)
Trial: 21502571
Drug: Atopaxar 50
RxNorm normalized name: Atopaxar
DrugBank: Atopaxar (DB12046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopaxar 50 mg daily
Trial: 21502571
Drug: Atopaxar 100
RxNorm normalized name: Atopaxar
DrugBank: Atopaxar (DB12046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopaxar 100 mg daily
Trial: 21502571
Drug: Atopaxar 200
RxNorm normalized name: Atopaxar
DrugBank: Atopaxar (DB12046)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopaxar 200 mg daily
Trial: 21502571
Drug: Atopaxar (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopaxar (higher doses)
Trial: 19662793
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose solution (1000 mL) one day before surgery
Trial: 19662793
Drug: Postoperative non‐glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative non‐glucose crystalloid solutions
Trial: 19662793
Drug: Postoperative use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative use of insulin
Trial: 19662793
Drug: Postoperative replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative replacement with cristalloids and insulin
Trial: 16445447
Drug: Intracameral mydriatics
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral mydriatics (ICM) solution
Trial: 15538125
Drug: Augmentation strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation strategy with risperidone
Trial: 8176922
Drug: Three courses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of cisplatinum containing combination chemotherapy
Trial: 8176922
Drug: Less than
RxNorm normalized name: IgA less than or equal to 50 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less than three courses of chemotherapy
Trial: 27439370
Drug: Abediterol 5
RxNorm normalized name: Abediterol
DrugBank: Abediterol (DB12100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abediterol 5 μg
Trial: 27439370
Drug: Abediterol 10
RxNorm normalized name: Abediterol
DrugBank: Abediterol (DB12100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abediterol 10 μg
Trial: 22078184
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of MPA 25 mg + E(2)-Cyp 5 mg
Trial: 22078184
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of MPA 25 mg + E(2)-Cyp 5 mg
Trial: 22078184
Drug: Both SC
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both SC and IM administration
Trial: 18077124
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance therapy throughout pregnancy
Trial: 16365743
Drug: Cisplatin 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 12.5 mg/m(2) plus radiation 36 Gy
Trial: 16365743
Drug: Taxol 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxol 40 mg/m(2)/carboplatin AUC 1.5 plus radiation 40 Gy
Trial: 11105938
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg per hour)
Trial: 8815669
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (catheters thoroughly washed before microwave treatment)
Trial: 2533878
Drug: 4% erythromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% erythromycin and zinc combination (Zineryt)
Trial: 335571
Drug: dl-alpha-tocopheryl nicotinate
RxNorm normalized name: DL-alpha tocopheryl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl-alpha-tocopheryl nicotinate (600 mg, 6 capsules a day)
Trial: 30040242
Drug: Nonanimal chondroitin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonanimal chondroitin sulfate (800 mg tablet)
Trial: 25141240
Drug: Intact ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact ER OC/APAP 30/1300 mg
Trial: 25141240
Drug: Intact IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact IR OC/APAP 30/1300 mg
Trial: 25141240
Drug: Intact ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact ER OC/APAP 15/650 mg
Trial: 25141240
Drug: Crushed ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed ER OC/APAP 30/1300 mg
Trial: 20659607
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 microg.kg(‐1).h(‐1) followed by a reduction by half in the rate of infusion
Trial: 20659607
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg.kg(‐1).h(‐1) followed by a reduction by half in the rate of infusion
Trial: 17987388
Drug: Self-administered with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered with telephone support (SA)
Trial: 17987388
Drug: Group-administered (PA)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-administered (PA)